Company Overview
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue -95.6%.
- 5-Year Trend Long-term compounding — revenue CAGR 4.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 4.05% |
| 1 Year: | -95.62% |
Stock Price Performance
| 1 Year: | -78.78% |
| 6 Months: | -44.97% |
| 3 Months: | -44.73% |
| 1 Month: | +6.57% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)49.41 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 85.8% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ATOS Atossa Therapeutics, Inc. PHARMA | 2.52 | -0.58 | $25.15M | 0.00% | -94.38% | -89.23% | 4.05% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2013 | Sep 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 326.08K | 76.60K | 24.12K | 9.88K | 3.43K | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | 103.92K | 50.66K | 24.12K | 9.88K | 3.43K | 0 | 0 | 458.84K | 0 | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | -2.58M | -3.50M | -2.41M | -3.19M | -3.25M | -3.27M | -3.17M | -3.84M | -2.33M | -1.72M | -1.56M | -1.70M | -1.90M | -2.06M | -1.87M | -4.14M | -3.31M | -4.06M | -7.29M | -3.30M | -2.94M | -3.94M | -3.51M | -3.53M | -7.00M | -5.16M | -4.75M | -6.59M | -8.21M | -7.10M | -7.79M | -7.47M | -6.98M | -7.11M | -6.38M | -7.41M | -9.04M | -9.25M | -9.87M | -8.69M |
| Net Income | -2.58M | -3.50M | -2.41M | -3.19M | -3.25M | -3.34M | -3.15M | -4.32M | -2.33M | -1.72M | 204.69K | -1.70M | -2.24M | -2.18M | -1.87M | -4.14M | -3.31M | -4.07M | -7.26M | -3.29M | -2.95M | -3.91M | -3.49M | -3.54M | -7.04M | -5.20M | -4.79M | -6.67M | -8.01M | -6.28M | -9.83M | -6.23M | -5.88M | -6.05M | -7.23M | -6.72M | -8.42M | -8.69M | -9.59M | -8.49M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.05 | -0.08 | -0.05 | -0.05 | -0.05 | -0.06 | -0.78 | -0.07 | -0.07 | -1.11 | -0.95 |
| R&D Expense | 189.96K | 321.11K | 422.50K | 510.77K | 923.17K | 565.80K | 373.47K | 948.96K | 149.97K | 168.99K | 85.00K | 544.30K | 824.09K | 742.45K | 470.98K | 1.47M | 1.42M | 1.45M | 2.61M | 1.68M | 938.62K | 1.65M | 1.66M | 1.38M | 3.80M | 2.21M | 1.50M | 3.43M | 5.16M | 3.51M | 3.71M | 4.47M | 3.75M | 3.55M | 3.41M | 4.16M | 5.50M | 5.37M | 4.78M | 4.90M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | 1.50K | 481.84K | 632.56K | 40.14K | 1.76K | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | -95.69K | 416.21K | 137.09K | 40.14K | -130.65K | - | - | - | - | - | - | - | - | - | - |
| Operating Income | - | -3.43M | -5.07M | -10.78M | -12.17M | -12.76M | -7.97M | -7.65M | -11.43M | -17.27M | -14.61M | -20.52M | -27.69M | -31.38M | -27.62M | -37.14M |
| Net Income | -1.09M | -3.44M | -5.08M | -10.78M | -14.66M | -15.76M | -6.37M | -8.12M | -11.40M | -17.24M | -17.83M | -20.61M | -26.96M | -30.09M | -25.50M | -34.77M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | -0.21 | -0.24 | -3.04 | -4.04 |
| R&D Expense | - | - | 1.97M | 1.11M | 1.11M | 2.36M | 770.43K | 2.33M | 4.21M | 6.65M | 6.61M | 9.21M | 15.08M | 17.33M | 14.12M | 21.18M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Apr 2009 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | - | 3.07M | 6.83M | 12.01M | 11.76M | 6.24M | 4.14M | 8.16M | 11.72M | 14.49M | 42.84M | 141.26M | 123.53M | 96.25M | 76.44M | 47.61M |
| Total Equity | 54.00K | 31.68K | -851.85K | 1.56M | 5.18M | 10.60M | 9.50M | 3.74M | 3.10M | 6.94M | 8.81M | 13.16M | 27.17M | 138.14M | 117.96M | 91.02M | 71.48M | 39.35M |
| Cash & Equivalents | 0 | - | 10.25K | 1.91M | 1.73M | 6.34M | 8.50M | 3.72M | 3.03M | 7.22M | 10.38M | 12.58M | 39.55M | 136.38M | 110.89M | 88.46M | 71.08M | 41.30M |
| Total Liabilities | - | - | - | - | - | 1.41M | 2.27M | 2.50M | 1.05M | - | 2.92M | 1.33M | 15.67M | 3.13M | 5.57M | 5.24M | 4.97M | 8.26M |
| Current Liabilities | - | - | - | 1.51M | 1.65M | 1.40M | 2.26M | 2.50M | 1.05M | 1.23M | 2.92M | 1.32M | 15.67M | 3.13M | 5.57M | 5.24M | 4.97M | 8.26M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2011 | Dec 2012 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -3.49M | -3.90M | -10.56M | -13.95M | -5.37M | -6.59M | -8.96M | -9.13M | -11.57M | -16.47M | -20.76M | -20.94M | -21.03M | -29.76M |
| Investing Cash Flow | -136.93K | -134.58K | -343.26K | -288.42K | -9.21K | - | -110.91K | -7.62K | -9.00K | -9.00K | -4.73M | -14.00K | -19.00K | -23.00K |
| Financing Cash Flow | 5.53M | 3.85M | - | - | 4.70M | 10.78M | 12.29M | 11.34M | 38.55M | 113.30M | 0 | -1.48M | 3.67M | 0 |
| Capital Expenditure | - | - | - | - | - | - | -110.91K | -7.62K | -9.00K | -9.00K | -27.00K | -14.00K | -19.00K | -23.00K |
| Free Cash Flow | - | - | - | - | - | - | -9.07M | -9.14M | -11.58M | -16.48M | -20.79M | -20.95M | -21.05M | -29.79M |
| Share Buybacks | - | - | - | - | - | - | - | - | - | - | 0 | 1.48M | 0 | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | -6,379.3% | 86.4% | 21.7% | 100.0% | -7,431.9% | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | -228,612.7% | -1,052.0% | -1,704.9% | -30,323.0% | -725,746.2% | - | - | - | - | - | - | - | - | - | - |
| Net Margin % | - | -229,484.5% | -1,054.3% | -1,704.9% | -36,518.8% | -896,491.6% | - | - | - | - | - | - | - | - | - | - |
| ROE % | 127.6% | -220.7% | -98.2% | -101.7% | -154.3% | -421.2% | -205.6% | -117.1% | -129.5% | -131.0% | -65.6% | -14.9% | -22.9% | -33.1% | -35.7% | -88.4% |
| ROCE % | - | -219.9% | -97.9% | -101.7% | -128.1% | -341.0% | -257.3% | -110.2% | -129.9% | -131.1% | -53.8% | -14.9% | -23.5% | -34.5% | -38.6% | -94.4% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Vanguard Capital Management LLC | 3.62% | 361.75K | $803.08K |
| 2 | Ameriprise Financial, Inc. | 2.59% | 258.23K | $573.28K |
| 3 | Blackrock Inc. | 1.65% | 164.36K | $364.87K |
| 4 | Renaissance Technologies, LLC | 1.32% | 132.04K | $293.13K |
| 5 | Geode Capital Management, LLC | 0.93% | 92.38K | $205.09K |
| 6 | UBS Group AG | 0.83% | 82.62K | $183.42K |
| 7 | Jane Street Group, LLC | 0.57% | 56.60K | $125.66K |
| 8 | Vanguard Fiduciary Trust Co | 0.53% | 52.58K | $116.73K |
| 9 | Millennium Management Llc | 0.47% | 46.51K | $103.25K |
| 10 | State Street Corporation | 0.40% | 39.76K | $88.27K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ATOS
Atos Group stock plunges to €25.88, below all its moving averages - Idéal Investisseur
<a href="https://news.google.com/rss/articles/CBMiwwFBVV95cUxQZW1yWnl1N1pXSThmSnZYVG9vblNaLTJKZ0ZxbW9SZTRtRTh1d0NsWFdmU2VQb1lBNnF2Q1RlQ1lsS044SGdyN1diRmVPR3VpdW56ei00X1RiUTRyUExZNzU1bFRkakJXQW1WV2ZZSEExRnNaMFlNUktwYUxwSFdKeVgwZXg0MTItOWpScE…
We're A Little Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi6wFBVV95cUxQNUpXams3d05UWXBVeXFuNUwzZG01a2MtYXJHM1AtQ2pRVFdxYW9YeS05QjlndHRUakJOblB2aFRaRkhYM3U5S3Q4dUppUkJ3TjhEcjduSDNQTFVMUjhZV2g0cU1XTXFqU1F0YXdoWGNVVkFBTmhteTh1b2s5N0ZKUVRFbm9yNEZQWEVFdV…
Atossa Therapeutics Announces Registered Direct Offering of up to $16.5 Million in Gross Proceeds - PR Newswire
<a href="https://news.google.com/rss/articles/CBMi5wFBVV95cUxNRjNZMk51a1lKYjRHV1AycHdqR1I1SzdpeHpPckJxZWhSR1JvLXd6dWh6bjkwVHVRdUpCUE9qVzNwLXlaTFpVXy1UUHFMdTNiTkRXTlFLYkx3U1ZnTEdZejQyejNVY0hBb2Z1MThQX29XcUR6R25IajJNeFpXT0M5QUo3RnU3MlBsSFBGOU…
Atos H1 2026 slides show margin gains, but shares sink 31% on growth - Investing.com
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxQVFdkNGhuclNCLVZUUmROYjFUWDkxZjRjMER1MFJiXzY3WkRlTGZSTTdWR3NETmJNaFk1UnJnMUk1bXlPNmtFUGlkQ2pxejJjOXFXSm9xRHhSbVU1Z2tqY29iX3dSSzVKRldMUUdtTS04YnljcFRlT3JZU1BoOHdTdUNWQ1R4SURmX3dST1…
Five New Compounds Show Activity in Breast Cancer Models With ESR1 Mutations - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxNeHNZNUF6SjFDbkl4UWZ0SVFEUVQzTVNzNHowNkRoSjdxRnloVjBpRGFOQUllT0FkaEtubXVVYkhaa3hjSlM5alo3SXRxZ0JwRzRtMDd5alc0c2kyTVpXblZIQmZoSGJoZzNSdkFNYngxU1E0X3VjOGp0TkdyUlRZZ2l6Szk3cU1MYXp0dk…
Atos Group Stock (ATO) - Quote Euronext Paris - marketscreener.com
<a href="https://news.google.com/rss/articles/CBMia0FVX3lxTE5fdHJfTU5xRFFMa3JPVll0N2Jya01WS3dGYUM5WG1VY1A1Zk01akdfV1J2NndsRWtBYXBVRlpRaS1lbVNCZmhFZVpyb25kU1pWWUF4UTdCSWQzd3Y0QW83UUxHV25RX2Q5S0V3?oc=5" target="_blank">Atos Group Stock (ATO) …
ATOS — Frequently Asked Questions
What is the current share price of Atossa Therapeutics, Inc. (ATOS)?
As of 2026-09-19 21:16 PDT, Atossa Therapeutics, Inc. (ATOS) trades at $2.52 on NasdaqCM. Its 52-week range is $1.75 to $17.70.
What is the market capitalisation of ATOS?
Atossa Therapeutics, Inc. (ATOS) has a market capitalisation of $25.15M on NasdaqCM.
What is the P/E ratio of ATOS?
ATOS trades at a trailing price-to-earnings (P/E) ratio of -0.58. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.89.
What is the return on equity (ROE) of ATOS?
ATOS has a return on equity (ROE) of -89.23%. Its return on capital employed (ROCE) is -94.38%.
Is ATOS a good stock to buy?
This page provides a data-driven analysis of Atossa Therapeutics, Inc. (ATOS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.